This is a summary of the European public assessment report (EPAR) for Edarbi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Edarbi.
Therapeutic Indication
### Therapeutic indication Edarbi is indicated for the treatment of essential hypertension in adults.
Therapeutic Area (MeSH)
ATC Code
C09CA09
ATC Item
azilsartan medoxomil
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Azilsartan medoxomil | N/A | 阿利沙坦酯 |
EMA Name
Edarbi
Medicine Name
Edarbi
Aliases
N/ANo risk management plan link.
